Performance analysis of UroGen Pharma (URGN)
Annual Return
Over the past 3 years, URGN has had an average annual return of +67.82%, outperforming the benchmark SPY, which returned +19.63% annual.
Over the past 5 years, URGN has had an average annual return of +22.31%, outperforming the benchmark SPY, which returned +12.73% annual.
Since May 4, 2017, URGN has had an average annual return of +13.18%, underperforming the benchmark SPY, which returned +15% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| +86.93% | +119.91% | -29.00% | +69.11% | -6.73% | -47.22% | -46.00% | -22.50% | +15.72% | +166.17% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -16.27% | +10.66% | -17.14% | +32.54% | +18.05% | +30.82% | +18.97% | +86.93% | |||||
| 2025 | +3.39% | -14.08% | +16.91% | +5.25% | -63.57% | +223.11% | +39.12% | +2.05% | +2.57% | +2.61% | +40.75% | -18.71% | +119.91% |
| 2024 | +4.66% | +16.76% | -18.17% | -7.87% | -3.76% | +26.16% | -1.97% | -15.44% | -8.70% | -3.46% | +3.58% | -16.14% | -29.00% |
| 2023 | +17.13% | -0.86% | -10.30% | +25.44% | -14.57% | +4.53% | +109.29% | -19.30% | -19.86% | -19.98% | +17.66% | +13.73% | +69.11% |
| 2022 | -18.83% | -22.27% | +45.15% | -18.94% | -24.65% | +53.96% | -4.27% | -4.98% | +11.67% | +42.43% | -27.68% | +3.51% | -6.73% |
| 2021 | +22.47% | -13.68% | +2.25% | -0.15% | -9.41% | -13.34% | +1.50% | +13.68% | -4.55% | +2.26% | -29.71% | -21.33% | -47.22% |
| 2020 | -11.87% | -7.31% | -34.56% | +24.50% | +5.67% | +11.29% | -15.43% | +13.58% | -23.12% | +16.75% | -7.86% | -13.16% | -46.00% |
| 2019 | -3.81% | -7.10% | -4.00% | -2.68% | -5.26% | +5.52% | -5.12% | -0.44% | -29.81% | -5.04% | +39.82% | +5.47% | -22.50% |
| 2018 | +32.01% | +7.21% | -5.64% | +12.74% | +7.32% | -17.23% | -9.16% | +6.93% | -2.28% | -15.50% | +22.88% | -12.20% | +15.72% |
| 2017 | +27.68% | +1.17% | +0.56% | +31.33% | +32.16% | +0.67% | +27.23% | -7.83% | +166.17% |
Drawdown analysis of UroGen Pharma (URGN)
The maximum drawdown for the URGN was -93.98%, occurring on May 27, 2025. This drawdown has not yet recovered.
The current URGN drawdown is -32.99%.
Since May 4, 2017 URGN has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 1 time
- 20% or more: 2 times
- 10% or more: 8 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -93.98% | May 18, 2018 | 1764 | May 27, 2025 | Ongoing | Ongoing | Ongoing |
| -20.07% | May 30, 2017 | 12 | Jun 15, 2017 | 7 | Jun 26, 2017 | 19 |
| -18.48% | Jan 25, 2018 | 7 | Feb 5, 2018 | 19 | Mar 5, 2018 | 26 |
| -16.62% | Sep 14, 2017 | 26 | Oct 20, 2017 | 9 | Nov 2, 2017 | 35 |
| -15.97% | Mar 14, 2018 | 12 | Apr 2, 2018 | 1 | Apr 3, 2018 | 13 |
| -14.93% | Nov 13, 2017 | 21 | Dec 13, 2017 | 13 | Jan 3, 2018 | 34 |
| -13.38% | Jun 27, 2017 | 38 | Aug 21, 2017 | 7 | Aug 30, 2017 | 45 |
| -11.40% | Apr 4, 2018 | 18 | Apr 30, 2018 | 14 | May 18, 2018 | 32 |
| -5.75% | Jan 16, 2018 | 2 | Jan 18, 2018 | 2 | Jan 22, 2018 | 4 |
| -4.08% | May 16, 2017 | 1 | May 17, 2017 | 1 | May 18, 2017 | 2 |
| -3.88% | Jan 3, 2018 | 1 | Jan 4, 2018 | 7 | Jan 16, 2018 | 8 |
| -3.19% | May 11, 2017 | 1 | May 12, 2017 | 1 | May 15, 2017 | 2 |
| -2.61% | Mar 9, 2018 | 2 | Mar 13, 2018 | 1 | Mar 14, 2018 | 3 |
| -2.59% | May 22, 2017 | 3 | May 25, 2017 | 2 | May 30, 2017 | 5 |
| -2.21% | Sep 7, 2017 | 1 | Sep 8, 2017 | 2 | Sep 12, 2017 | 3 |
| -2.06% | Mar 5, 2018 | 2 | Mar 7, 2018 | 2 | Mar 9, 2018 | 4 |
| -1.84% | Jan 22, 2018 | 1 | Jan 23, 2018 | 1 | Jan 24, 2018 | 2 |